Krebs Biochemicals & Industries Limited (KREBSBIO) Fair Value & Analysis
Healthcare · IN · Market cap ₹1.3B
Fair value as of: Jul 3, 2026
From 3 valuation models · updated today
Share price −8.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹40.07 – ₹86.68 · fair‑value band ₹6.79 – ₹17.97 · the ₹59.02 price screens above the ₹12.66 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Krebs Biochemicals & Industries Limited (KREBSBIO) currently trades at ₹59.02, while our model-based Fair Value estimate is ₹12.66 — implying the stock looks roughly 78.5% overvalued today. We read business quality at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Krebs Biochemicals & Industries Limited generated revenue of ₹237M at a net margin of -71.4%. Revenue grew 11.6% year over year. Net debt stands at ₹2.2B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Krebs Biochemicals & Industries Limited reported revenue of ₹237M in FY2026 versus ₹597M in FY2022, a compound −20.6%/yr. Reported net income was −₹169M in FY2026.
Is KREBSBIO fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Krebs Biochemicals & Industries Limited (KREBSBIO) undervalued?
What is the fair value of KREBSBIO?
What is the quality score of KREBSBIO?
What is the revenue of Krebs Biochemicals & Industries Limited (KREBSBIO)?
What is the net profit margin of KREBSBIO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.